1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
RPG Life Sciences Limited

RPG Life Sciences Limited

RPGLIFE.BO
RPG Life Sciences LimitedIN flagBombay Stock Exchange
2,419.65
INR
+3.00
- -
40.00BMarket Cap
RPG Life Sciences Limited
RPGLIFE.BO
(Bombay Stock Exchange)

Recent

price

2,419.65

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
112.99
116.61
134.04
142.45
146.25
168.67
174.06
203.85
195.85
223.2
231.81
264.32
307.81
349.16
395.11
- -
397.26
Revenue per Share
7.69
0.51
2.67
32.29
0.6
7.03
12.7
8.13
6.54
17.54
24.19
31.13
40.9
53
110.8
- -
110.52
Basic EPS, GAAP
1.9
4.2
-0.17
-11.62
-7.68
19.84
4.43
-0.48
15.78
23.84
30.09
24.67
35.12
15.19
25.29
- -
- -
Free Cash Flow per Basic Share
1.29
1.58
0.79
1.18
2.31
2.87
0.15
3.34
2.9
7.72
- -
7.2
9.6
12
16
- -
- -
Dividend per Share
8
8
23.25
49.98
49.62
50.49
62.8
67.48
70.96
80.68
104.79
128.56
159.9
200.56
294.71
- -
- -
Book Value per Share
30.93
32.05
33.95
64.59
64.85
66.66
55.95
60.44
65.49
81.44
108.42
133.68
165.79
209.7
307.03
- -
- -
Tangible Book Value per Share
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
- -
17
Basic Weighted Avg Shares
1,868
1,928
2,216
2,356
2,418
2,789
2,879
3,372
3,239
3,692
3,834
4,372
5,091
5,775
6,534
7,075
6,569
Sales/Revenue/Turnover
12.71
4.46
3.21
0.53
2.17
5.2
6.24
7.77
5.92
11.98
14.27
16.41
17.46
19.41
21.15
17.75
20.52
Operating Margin (%)
95
102
99
106
114
102
118
143
153
164
165
157
155
171
214
215
213
Depreciation Expense
127
8
44
534
10
116
210
134
108
290
400
515
676
877
1,832
1,152
1,828
Net Income, GAAP
27.25
51.15
- -
17.81
- -
- -
16.85
33.94
28.17
20.41
25.35
29.64
26.22
25.61
21.32
25.31
21.32
Effective Tax Rate (%)
6.8
0.44
1.99
22.67
0.41
4.17
7.3
3.99
3.34
7.86
10.43
11.78
13.29
15.18
28.04
16.28
27.82
Profit Margin (%)
-25
-31
-124
202
189
101
177
219
193
432
962
1,268
1,613
1,671
3,454
3,989
- -
Working Capital
248
207
105
4
3
2
160
102
66
15
7
3
- -
- -
- -
133
- -
LT Debt
748
741
762
1,258
1,252
1,266
1,470
1,548
1,605
1,766
2,164
2,558
3,076
3,748
5,305
6,054
- -
Total Equity
16.22
3.69
- -
0.77
3.52
9.51
8.86
8.68
6.81
18.36
20.18
21.31
23.32
24.53
24.12
16.25
- -
Return on Invested Capital (%)
34.86
7.98
- -
60.75
3.52
12.75
18.15
10.15
8.56
20.34
25.33
26.66
28.39
29.52
44.86
44.5
575.96
Return on Capital (%)
100.53
6.42
17.07
88.2
1.21
14.04
22.43
12.48
9.44
23.13
26.08
26.68
28.36
29.41
44.74
46.01
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'25
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
17
- -
Market Capitalization
36,005
37,665
41,018

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'25
Jun'26
Total Current Assets
- -
4,652
- -
Cash, Cash Equivalents & STI
- -
2,646
- -
Accounts Receivable, Net
- -
868
- -
Inventories
- -
930
- -
Total Current Liabilities
- -
1,198
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
17.36%
23.18%
14.1%
Free Cash Flow
-340.47%
13.83%
35.07%
Net Income, GAAP
39.3%
32.31%
-37.15%
Sales/Revenue/Turnover
9.96%
13.07%
8.28%
Total Cash Common Dividend
- -
26.98%
50%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,478
1,536
1,537
1,224
5,775
2025
1,654
1,722
1,727
1,431
6,534
2026
1,689
1,800
1,769
- -
7,075

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
13.36
15.64
16
- -
53
2025
16.18
2.54
21.12
70.96
110.8
2026
15.9
13.38
18.08
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
12
2025
- -
- -
- -
- -
16
2026
- -
- -
- -
- -
- -
Similar Companies
Wanbury Limited (WANBURY.NS)
THC Biomed Intl Ltd. (THCBF)
DMK Pharmaceuticals Corporation (DMKPQ)
Mayinglong Pharmaceutical Group Co., Ltd. (600993.SS)
Sunflower Pharmaceutical Group Co.,Ltd (002737.SZ)
Endo International plc (ENDP)
Business
RPG Life Sciences Limited is an Indian pharmaceutical company primarily engaged in the manufacturing and marketing of bulk drugs, pharmaceutical formulations, active pharmaceutical ingredients (APIs), generic formulations, and specialty chemicals. Its core product offerings include a broad range of APIs across therapeutic segments such as anti-infectives, cardiovascular, anti-diabetics, central nervous system (CNS) drugs, and proprietary formulations. The company also manufactures intermediates and specialty chemicals catering to pharmaceutical and other industries. RPG Life Sciences operates in various geographic markets including India and international markets, emphasizing its presence in both domestic and global pharmaceutical sectors. Founded in 1985 and headquartered in Mumbai, India, the company serves healthcare providers, pharmaceutical distributors, and industrial clients through a diversified product portfolio. In the last 1-2 years, RPG Life Sciences has focused on expanding its global footprint and enhancing its product pipeline. The company has engaged in strategic partnerships and alliances to advance its pharmaceutical research and development capabilities, alongside launching new formulations and APIs aimed at addressing unmet therapeutic needs. Recent operational changes include efforts to strengthen manufacturing capacities and quality standards to meet regulatory requirements in global markets. The company has also explored expansion initiatives to diversify its product mix and improve supply chain efficiencies, reflecting a strategic shift towards becoming a more integrated pharmaceutical player with enhanced competitiveness and market reach. RPG Life Sciences operates primarily within the pharmaceutical industry, specifically targeting the bulk drugs and formulations segment with products serving various clinical areas. The company’s customer base includes pharmaceutical companies, hospitals, healthcare professionals, and industrial clients requiring specialty chemicals. Headquartered in Mumbai, the company maintains manufacturing facilities compliant with international regulatory standards and continues to innovate in drug development and manufacturing processes. As part of the RPG Group, RPG Life Sciences benefits from strong parent company support and a wide network of subsidiaries and joint ventures that facilitate its operations and strategic growth both in India and abroad.